(Q37882584)

24 August 2017

1 reference

title

Milestones in movement disorders clinical trials: advances and landmark studies (English)

1 reference

24 August 2017

1 reference

Charles Warren Olanow

series ordinal

1

object named as

C Warren Olanow

1 reference

24 August 2017

3

Karl Kieburtz

1 reference

24 August 2017

Kathryn B Wunderle

2

1 reference

PubMed ID

21626545

24 August 2017

language of work or name

English

0 references

publication date

1 May 2011

1 reference

24 August 2017

1 reference

24 August 2017

26

1 reference

24 August 2017

6

1 reference

24 August 2017

1003-1014

1 reference

The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations

24 August 2017

1 reference

Systematic evaluation of rating scales for impairment and disability in Parkinson's disease

21 January 2018

1 reference

Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan

21 January 2018

1 reference

Utility of an objective dyskinesia rating scale for Parkinson's disease: inter- and intrarater reliability assessment.

21 January 2018

1 reference

Quantifying the impact of dyskinesias in PD: the PDYS-26: a patient-based outcome measure

21 January 2018

1 reference

The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study.

21 January 2018

1 reference

Assessment of cognition in Parkinson's disease.

21 January 2018

1 reference

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease

21 January 2018

1 reference

Clinical trial end points: on the road to nowhere?

21 January 2018

1 reference

A responsive outcome for Parkinson's disease neuroprotection futility studies

21 January 2018

1 reference

"Disease-modification" trials in Parkinson disease: target populations, endpoints and study design

21 January 2018

1 reference

The effect of deprenyl (selegiline) on the natural history of Parkinson's disease

21 January 2018

1 reference

Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease

21 January 2018

1 reference

The effect of deprenyl and levodopa on the progression of Parkinson's disease

21 January 2018

1 reference

Levodopa and the progression of Parkinson's disease

21 January 2018

1 reference

Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease

21 January 2018

1 reference

SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT: pharmacological characterization of brain uptake in nonhuman primates.

21 January 2018

1 reference

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study

21 January 2018

1 reference

Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression

21 January 2018

1 reference

The role of radiotracer imaging in Parkinson disease

21 January 2018

1 reference

How valid is dopamine transporter imaging as a surrogate marker in research trials in Parkinson's disease?

21 January 2018

1 reference

Predictive Probability Early Termination Plans For Phase II Clinical Trials

21 January 2018

1 reference

A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS.

21 January 2018

1 reference

A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease

21 January 2018

1 reference

A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease

21 January 2018

1 reference

A futility study of minocycline in Huntington's disease

21 January 2018

1 reference

Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial

21 January 2018

1 reference

Futility studies: spending a little to save a lot.

21 January 2018

1 reference

A double-blind, delayed-start trial of rasagiline in Parkinson's disease

21 January 2018

1 reference

A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease

21 January 2018

1 reference

Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed?

21 January 2018

1 reference

Timing of treatment initiation in Parkinson's disease: a need for reappraisal?

21 January 2018

1 reference

Rationale for delayed-start study of pramipexole in Parkinson's disease: the PROUD study

21 January 2018

1 reference

Design and analysis of two-period studies of potentially disease-modifying treatments.

21 January 2018

1 reference

Using global statistical tests in long-term Parkinson's disease clinical trials

21 January 2018

1 reference

Fetal nigral transplantation as a therapy for Parkinson's disease

21 January 2018

1 reference

Core assessment program for intracerebral transplantations (CAPIT)

21 January 2018

1 reference

Transplantation of embryonic dopamine neurons for severe Parkinson's disease

21 January 2018

1 reference

A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease

21 January 2018

1 reference

Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease

21 January 2018

1 reference

Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD.

21 January 2018

1 reference

Intrastriatal implantation of human retinal pigment epithelial cells attached to microcarriers in advanced Parkinson disease

21 January 2018

1 reference

The ethical problems with sham surgery in clinical research

21 January 2018

1 reference

Use of placebo surgery in controlled trials of a cellular-based therapy for Parkinson's disease

21 January 2018

1 reference

What is the risk of sham surgery in Parkinson disease clinical trials? A review of published reports

21 January 2018

1 reference

Effects of perceived treatment on quality of life and medical outcomes in a double-blind placebo surgery trial

21 January 2018

1 reference

Science and ethics of sham surgery: a survey of Parkinson disease clinical researchers

21 January 2018

1 reference

Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease.

21 January 2018

1 reference

A randomized trial of deep-brain stimulation for Parkinson's disease.

21 January 2018

1 reference

Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial

21 January 2018

1 reference

Pallidal versus subthalamic deep-brain stimulation for Parkinson's disease.

21 January 2018

1 reference

Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial

21 January 2018

1 reference

Expectation and the placebo effect in Parkinson's disease patients with subthalamic nucleus deep brain stimulation.

21 January 2018

1 reference

Defining disease-modifying therapies for PD--a road map for moving forward

21 January 2018

1 reference

Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results

21 January 2018

1 reference

Unified Huntington's disease rating scale: Reliability and consistency

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/MDS.23727

1 reference

24 August 2017

1 reference

PubMed ID

21626545